Catalyst Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Catalyst Capital Advisors's BMY Position: Q2 2022 in Review
Catalyst Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2022, closing a stake of 2,210 shares — an estimated $161K sold.
Catalyst Capital Advisors first reported a position in BMY in Q1 2020 and held it in 9 quarters. The position peaked at $1.49M in Q1 2020. 2,537 funds tracked by Wall St. Rank hold BMY as of Q2 2022.
- Catalyst Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2022 after selling out during the quarter.
- Catalyst Capital Advisors sold 2,210 Bristol-Myers Squibb shares in Q2 2022, an estimated $161K.
- Catalyst Capital Advisors first reported a position in Bristol-Myers Squibb in Q1 2020 and held it in 9 quarters.
- Catalyst Capital Advisors's Bristol-Myers Squibb position peaked at $1.49M in Q1 2020.
- 2,537 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.
Based on Catalyst Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.